002412.SHE Hunan Hansen Pharmaceutical Co Ltd
- Market cap
- CNY 3.88B
- P/E
- 13.8x
- P/B
- 1.57x
- ROE
- 8.7%
- Dividend yield
- 0.04%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002412.SHE undervalued?
Graham number002412.SHE trades 1.9% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hunan Hansen Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Hunan Hansen Pharmaceutical Co Ltd yet.
Hunan Hansen Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hunan Hansen Pharmaceutical Co Ltd
Hunan Hansen Pharmaceutical Co., Ltd. engages in the production and sale of traditional Chinese preparations in China and internationally. The company offers medications for digestive, cardiovascular, cerebrovascular, and urological diseases, as well as for traumatology and diagnostic applications. It provides its products in various forms, including injections, mixtures, tablets, capsules, granules, syrups, decoctions, tinctures, and pills. Hunan Hansen Pharmaceutical Co., …
Full company profileHunan Hansen Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hunan Hansen Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 798M | 830M | 922M | 887M | 741M | 892M | 916M | 956M | 1.00B | 1.04B | 946M |
| Gross Profit | 558M | 594M | 674M | 648M | 514M | 635M | 649M | 693M | 754M | 804M | 739M |
| Operating Income | 95.3M | 131M | 166M | 188M | 119M | 150M | 189M | 235M | 253M | 242M | 208M |
| EBITDA | 145M | 187M | 225M | 247M | 175M | 208M | 238M | 281M | 296M | 281M | 238M |
| Net Income | 84.9M | 109M | 148M | 162M | 106M | 135M | 168M | 205M | 220M | 198M | 208M |
| EPS | 0.17 | 0.22 | 0.29 | 0.32 | 0.21 | 0.27 | 0.33 | 0.41 | 0.44 | 0.39 | 0.41 |
| Balance Sheet | |||||||||||
| Total Assets | 1.67B | 1.70B | 1.80B | 1.88B | 1.89B | 2.11B | 2.29B | 2.34B | 2.55B | 2.69B | 2.49B |
| Total Liabilities | 416M | 481M | 435M | 353M | 294M | 369M | 397M | 373M | 344M | 312M | 102M |
| Shareholders' Equity | 1.26B | 1.22B | 1.36B | 1.53B | 1.59B | 1.74B | 1.89B | 1.96B | 2.20B | 2.38B | 2.39B |
| Cash & Short-term Investments | 120M | 83.9M | 82.7M | 117M | 104M | 140M | 281M | 255M | 372M | 250M | 112M |
| Total Debt | 287M | 345M | 260M | 191M | 178M | 132M | 120M | 95.1M | 84.5M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 161M | 107M | 218M | 165M | 162M | 213M | 144M | 161M | 131M | 245M | - |
| Capital Expenditure | 44.9M | 50.2M | 64.5M | 35.7M | 129M | 229M | 11.5M | 19.5M | 11.6M | 11.1M | 16.5M |
| Free Cash Flow | 116M | 57.0M | 153M | 129M | 33.1M | -16.8M | 132M | 141M | 119M | 234M | 151M |
| Ratios | |||||||||||
| ROE | 6.7% | 8.9% | 10.8% | 10.6% | 6.7% | 7.7% | 8.8% | 10.4% | 10.0% | 8.3% | 8.7% |
| ROA | 5.1% | 6.4% | 8.2% | 8.6% | 5.6% | 6.4% | 7.3% | 8.8% | 8.6% | 7.4% | 8.4% |
| Net Profit Margin | 10.6% | 13.1% | 16.0% | 18.3% | 14.3% | 15.1% | 18.3% | 21.5% | 21.9% | 19.1% | 22.0% |
| Debt to Equity | 0.23x | 0.28x | 0.19x | 0.12x | 0.11x | 0.08x | 0.06x | 0.05x | 0.04x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hunan Hansen Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.04%
- Forward dividend
- 0.30 CNY
- Payout ratio
- 0.9%
- Ex-dividend date
- Jun 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.73M | 0.00 | 0.9% |
| 2024 | CNY 2.55M | 0.01 | 1.2% |
| 2023 | CNY 151M | 0.30 | 73.6% |
| 2022 | CNY 4.07M | 0.01 | 2.4% |
| 2021 | CNY 6.58M | 0.01 | 4.9% |
| 2020 | CNY 37.7M | 0.07 | 35.6% |
| 2019 | CNY 9.66M | 0.02 | 5.9% |
| 2018 | CNY 13.4M | 0.03 | 9.1% |
| 2017 | CNY 162M | 0.32 | 149.3% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.7:1 on May 30, 2019.
Who owns Hunan Hansen Pharmaceutical Co Ltd
- Insiders 54.04%
- Institutions 1.09%
- Public & others 44.87%
- Shares outstanding 503M
- Free float 249M
Hunan Hansen Pharmaceutical Co Ltd company profile
- Company name
- Hunan Hansen Pharmaceutical Co Ltd
- Ticker
- 002412.SHE
- ISIN
- CNE100000PK2
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 2,108
- Fiscal year end
- December
- Address
- No. 2688, Yincheng Avenue, Yiyang, China, 413000
- Phone
- 86 737 6351 0790
- Website
- hansenzy.com
About Hunan Hansen Pharmaceutical Co Ltd
Hunan Hansen Pharmaceutical Co., Ltd. engages in the production and sale of traditional Chinese preparations in China and internationally. The company offers medications for digestive, cardiovascular, cerebrovascular, and urological diseases, as well as for traumatology and diagnostic applications. It provides its products in various forms, including injections, mixtures, tablets, capsules, granules, syrups, decoctions, tinctures, and pills. Hunan Hansen Pharmaceutical Co., Ltd. was founded in 1998 and is based in Yiyang, China.
Hunan Hansen Pharmaceutical Co Ltd management
8- Mr. Zhengqing LiuChairman & CEO · born 1964
- Mr. Jianghong DaiVP, CFO & Board Secretary · born 1970
- Mr. Hua YangVP & MD of Hansen Research · born 1982
- Mr. Lingsong AoDirector & VP · born 1972
- Mr. Jianjun FuDirector & VP · born 1964
- Ms. Ai Hua LiuVice President · born 1971
- Mr. Zhijun LiuVice President · born 1982
- Zhirong GuoAccounting Supervisor